Barry Quart compensation by year
Heron Therapeutics Summary Compensation Table · all 7 fiscal years held| Component | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|
| Salary | $579,143 | $596,518 | $614,414 | $638,991 | $676,838 | $700,000 | $736,000 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $0 | $0 | $916,995 | $2,061,649 | $0 |
| Option awards | $2,976,744 | $3,391,524 | $4,815,660 | $4,916,373 | $3,366,895 | $2,268,479 | $0 |
| Non-equity incentive | $208,492 | $246,958 | $552,973 | $306,715 | $364,991 | $392,000 | $386,400 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $7,950 | $8,100 | $8,250 | $8,400 | $21,084 | $8,700 | $23,304 |
| Total | $3,772,329 | $4,243,100 | $5,991,297 | $5,870,479 | $5,346,803 | $5,430,828 | $1,145,704 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Heron Therapeutics, Inc. DEF 14A filed May 1, 2023, accession 0000950170-23-016042, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Heron Therapeutics, Inc. filed document, accession 0000950170-23-016042. Every figure is read from that document and cited to the page and table it appears in. Filed May 1, 2023.
Equity holdings
unvested awards at FY2022 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 130,929 | $327,323 | — |
| PSU | 29,166 | $72,915 | — |
| Option | 81,250 | — | $25.02 |
| Option | 240,363 | — | $10.55 |
| Option | 160,417 | — | $15.72 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Heron Therapeutics, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.
Heron Therapeutics’s named executive officers, FY2022
as the company reported each| Named executive officer | Role | FY2022 total |
|---|---|---|
| Kimberly Manhard | Executive Vice President, Drug Development | $1,447,107 |
| David Szekeres | Executive Vice President, Chief Commercial Officer | $1,429,231 |
| Barry Quart · this page | Former Chief Executive Officer | $1,145,704 |
Board service
Heron Therapeutics board · FY2021How this board is paid
Company policy: Heron Therapeutics pays directors a $50,000 cash retainer and $100,000 in RSUs. As stated in Heron Therapeutics's FY2021 proxy.
The full Heron Therapeutics compensation record
free company briefThis page is one person within Heron Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Heron Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Heron Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.